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Abstract Social cognition is described as the higher
mental processes that are engaged while people store, pro-
cess, and use social information to make sense of them-
selves and others. Aspects of social cognition include
emotion perception, social cue interpretation, attribution
style, and theory of mind, all of which appear disordered in
schizophrenia. Such social cognitive deficits are believed to
be important predictors of functional outcome in schizo-
phrenia, therefore they may represent a crucial treatment
target. Few studies have evaluated the influence of anti-
psychotic treatment on these deficits. The purpose of this
review is to examine the relationship between antipsychotic
treatment and social cognition, whether antipsychotics
improve social cognitive function, and if so to explore
differential medication effects. Comprehensive searches of
PsycINFO and MEDLINE/PUBMED were conducted to
identify relevant published manuscripts. Fifteen relevant
papers published in English were found, describing original
studies. On the basis of this review, we have drawn the
following conclusions: first, the results do not engender
optimism for the possibility that antipsychotic drugs can
specifically facilitate social recovery. Second, the actions of
antipsychotics on social cognition are inconclusive, due to
lack of standardization across research groups, leading to
inconsistencies between study designs, methods used, and
medication dosages. Third, large-scale longitudinal inves-
tigations are needed to explore the unclear relationships
between social cognition, symptoms, and functional out-
come. Other non-pharmacological treatments focusing on
training patients in the social cognitive areas may hold more
promise.
1 Introduction
Social cognition has been defined as the way we perceive,
interpret, and understand social information [1] or as ‘‘the
processes that allow a person to understand, act on, and
benefit from the interpersonal world’’ [2]. A further overall
definition was given by Adolphs [3] who described social
cognition as ‘‘the ability to construct representations of the
relation between oneself and others and to use those rep-
resentations flexibly to guide social behaviour.’’
Aspects of social cognition include emotion perception,
social cue interpretation, attribution style, and theory of
mind. Affect perception is the ability to infer emotional
information, in other words what a person is feeling, pre-
sented either in visual or auditory form. Social cue per-
ception refers to a person’s ability to ascertain social cues
from behaviour provided in a social context, and refers to a
person’s comprehension of social rules [4]. Attribution
style, known as a personalizing bias, refers to an individ-
ual’s own perception and interpretation of facts and events
[5]. The attribution of mental states, such as desires,
intentions, and beliefs, to other people has been referred to
as ‘‘theory of mind’’ (ToM) or ‘‘mentalising’’ [6, 7]. ToM
involves both the ability to understand that others have
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mental states different from one’s own, and the capability to
make correct inferences about the content of those mental
states [5].
The neurophysiological and neurochemical underpin-
nings of social cognition in schizophrenia are a scientific
domain that requires further exploration. Several neuro-
transmitters seem to play a considerable role in social
cognitive processes, and their circuitries are deemed to be
altered in schizophrenia. The hypothalamic peptides argi-
nine vasopressin (AVP) and oxytocin (OXT) have been
described as social hormones that may mediate social
behaviour [8] including social motivation, approach
behaviour [9], and ToM [10, 11]. Recently, abnormal
oxytocinergic and dopaminergic signalling in the amy-
gdalae has been proposed to explain dysfunction in the
social cognitive domain in schizophrenia [12].
Serotonin is another neurotransmitter linked to social
behaviour, including roles in cognition, mood, and
aggression, alongside motivation, energy levels, and sleep
[13, 14]. There is increasing interest in the correlation
between negative symptoms of schizophrenia and abnor-
mal neurotransmission at serotonin 5-HT2 receptors [15].
Dopamine appears as a key neurotransmitter in the
aetiopathogenesis of schizophrenia described as crucially
involved in the attribution process as well as emotional
perception, giving not only meaning but also salience to the
objects in our environment [16, 17]. Deregulation of the
dopaminergic system leads to the production of dopamine
regardless of incoming stimuli, which results in giving
meaning to their meta-representations, thereby creating a
misguided inner reality of actually meaningless objects.
This maladaptive attribution system created during psy-
chosis is very often implicated permanently in the patient’s
experience, regardless of pharmacological blocking of
excess dopamine [16].
A growing body of literature has shown consistently that
schizophrenia patients compared with healthy controls
present with social cognitive impairments that are relatively
stable and persistent, suggesting that it is a trait-dependent
rather than state-dependant aspect of the disorder [18–20].
These deficits have been widely described as modifying
patients’ behaviour when interacting with other people
(ToM deficits) [7, 20–22] and in recognizing emotions [23–
25] and other social information cues [18, 26]. Therefore,
social cognitive deficits are believed to be important pre-
dictors of functional outcome in schizophrenia [5, 27]. Such
deficits represent an obvious substrate for treatment in
schizophrenia.
Pharmacological treatment research on social cognition
in schizophrenia has been relatively limited: recent data on
the effects of second- and first-generation antipsychotics
(SGA/FGA) on various domains of social cognition remain
inconclusive.
This paper aims (1) to appraise current evidence on the
impact of antipsychotics upon social cognitive functioning
in schizophrenia, to find out if antipsychotics do really
improve social cognitive functions; and if yes, (2) to
explore differential medication effects on social cognition,
if any.
A comprehensive search of the PsycINFO and MED-
LINE/PUBMED databases for articles in English published
till 31 December 2012 was conducted. Within the domain
of social cognition, the following search terms were used:
emotion/affect perception, emotion/affect recognition,
attribution/attributional style, theory of mind/mentalising,
social cognition, social competence, and social cue per-
ception. Within the domain of psychopharmacology out-
come, the following terms were used: conventional
antipsychotics, atypical antipsychotics, atypicals, and
clinical trials.
Search terms for schizophrenia included the following:
psychosis, schizophrenia, and schizoaffective disorder.
1.1 Search Strategy
The following search keywords were used:
1. schizophrenia AND social cognition AND antipsy-
chotics; 224 articles, 15 utilised
2. schizophrenia AND emotion perception AND antipsy-
chotics; 63 papers, 6 utilised
3. schizophrenia AND facial affect AND antipsychotics;
29 papers, 4 utilised
4. schizophrenia AND theory of mind AND antipsychot-
ics; 14 papers, 3 utilised
5. schizophrenia AND attribution AND antipsychotics;
20 articles, 0 utilised
6. schizophrenia AND attributional style AND antipsy-
chotics; 3 articles, 1 utilised
7. schizophrenia AND social competence AND antipsy-
chotics; 33 articles, 2 utilised
8. schizophrenia AND social cue perception AND anti-
psychotics; 2 papers, 1 utilised
1.2 Inclusion Criteria
The papers were utilised in the current review if they
were written in English and had reported experimental
studies of aspects of social cognition in schizophrenia
treated with antipsychotic medication. Although 32 papers
were identified there was much overlap between the
results of individual searches: 15 papers in total were
accrued from all eight searches and are reviewed here
(see Table 1).
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2 The Place of Social Cognitive Deficit in Multifactorial
Models of Schizophrenia: Symptom,
or Neurocognitive Compromise?
The analysis of emotional behaviour in schizophrenia is
fundamental to the notion of dementia praecox introduced
by Kraepelin, and a question fielded by Bleuler on the basis
of ‘Affektivita¨t’: ‘‘What happened to feelings in dementia
praecox?’’ This has constituted and still constitutes a sci-
entific challenge [28]. While symptom-based approaches
have understandably dominated most aspects of pharma-
cological intervention in schizophrenia research, a limited
number of studies have investigated the effect of symptoms
on social cognition [29–33].
To the best of the authors’ knowledge, the majority of
studies fail to demonstrate a clear relationship between
overall symptom severity scores and performance on social
cognitive measures [29, 34–36].
However, there are suggestions that negative and dis-
organized symptoms may be related to social cognitive
functioning [21, 23, 31, 37, 38].
Relationships among social cognitive constructs and
negative symptoms are, however, not clear. Although some
overlap exists between negative symptoms and social cog-
nition in schizophrenia, according to participants at a
National Institute of Mental Health (NIMH) conference
where this issue was addressed [39] it is unwise to combine
the constructs at this point in time. The consensus was that it
is more informative to study negative symptoms and social
cognition separately and to analyse relationships between
them, until we know more about areas of convergence and
divergence. Regarding positive symptoms [32], there has
been some linkage between attributional style and paranoid
delusions [40]. There is virtually no literature that has
developed the relationship between disorganisation symp-
toms and social cognition.
Penn et al. [1] argued that multifactorial models of
schizophrenia, including only non-social cognitive pro-
cesses i.e. ‘neurocognition’, did not adequately explain the
social functioning impairment in schizophrenia. Subse-
quently, social cognition was seen as a key domain for
consideration during the first meeting of the NIMH-spon-
sored Measurement and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS) initiative [27] and
it was ultimately included as one of the seven domains
represented in the MATRICS Consensus Cognitive Battery
for clinical trials in schizophrenia [39].
Therefore, current accepted wisdom is that social cog-
nitive deficit is a variety of neurocognitive compromise; it
does not represent a symptom or group of symptoms by
itself. The development of objective tests to quantify
degrees of social cognitive impairment argues further for
the validity of this construct.
3 Does Antipsychotic Treatment Improve Social
Cognition?
Lewis and Garver [34] assessed facial affect recognition in
18 patients on haloperidol (5–20 mg/day) compared with
10 healthy controls in the course of their 2-week non-
randomised clinical trial. An impairment in facial affect
recognition was found in the schizophrenia group. This
deficit was not related to psychopathology symptom scores.
Bellack et al. [41] assessed the effects of clozapine and
risperidone on social skills at baseline, week 17, and week
29 in patients with schizophrenia using the Maryland
Assessment of Social Competence. No significant medi-
cation effect on social competence was found despite
clinical improvement on both medications. Similarly,
Herbener et al. [31] described no beneficial effect of anti-
psychotics after 1 month (nine patients on risperidone)
regarding facial affect recognition in 13 patients with first-
episode psychosis.
It is worth noting that these studies were not adequately
powered to draw definite conclusions. However, two influ-
ential randomised studies failed again to support the
hypothesis that antipsychotics improve social cognition [29,
42]. Harvey et al. [29] found that patients with schizophrenia
treated with either risperidone (n = 154; 2–8 mg/day) or
quetiapine (n = 135; 200–800 mg/day) for an 8-week per-
iod of double-blind treatment did not improve their facial
affect recognition, using the Penn Emotional Acuity Test.
Similarly, Sergi et al. [42] found no evidence of treatment-
related differences in social cognition in 73 patients with a
diagnosis of schizophrenia in an 8-week double-blind study
of risperidone, olanzapine, and haloperidol. Interestingly,
when the potential influence of changes in neurocognition
was statistically controlled for, there was no within-group
change in social cognition. This suggests that social cogni-
tion and neurocognition are not the same thing, in other
words, they vary independently of each other.
Alternatively, Gaebel and Wo¨lwer [23] and Roberts et al.
[38] demonstrated, respectively, significant improvement in
facial affect recognition in patients on FGAs (haloperidol or
perazine) and on the Social Cue Recognition Test in
patients treated with olanzapine (n = 117) or quetiapine
(n = 106) [Table 1]. Similarly Mizrahi et al. [21] studied
17 drug-free patients who then received antipsychotic
treatment for 6 weeks: the effect on psychotic symptoms
and ToM, using a hinting task, was measured every
2 weeks. The hinting task score was associated with nega-
tive and general symptom scores. Both the Positive and
Negative Syndrome Scale (PANSS) positive scores and
ToM improved after medication was started, particularly
during the first 2 weeks of antipsychotic treatment.
Surprisingly, Machado de Sousa and Hallak [43]
reported no differences in recognition accuracy or
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emotional intensity scores within the Facial Emotion
Recognition Task between patients on clozapine compared
with healthy controls. Since clozapine is a superior anti-
psychotic drug, this suggests that clozapine treatment may
have corrected any deficit. The analysis of individual
emotions, however, demonstrated a specific time-related
deficit affecting the recognition of fear and disgust.
Moreover, Harvey et al. [29] reported a similar apparent
differential effect in patients treated for 8 weeks with
quetiapine or risperidone: emotion perception remained
unchanged, whereas social competence improved. This
correlated with concurrent improvement in other aspects of
neuropsychological performance, such as executive func-
tion and memory.
3.1 Is There Any Differential Effect on Social
Cognition Between Antipsychotic Agents?
A number of influential studies have confirmed that SGAs
outperformed FGAs in a range of clinical efficacy param-
eters, including the domain of social cognition [32, 36, 44–
46]. It has been argued that SGAs’ strong affinity for 5-HT2
receptors [14] via the disinhibitory effect of serotonin
antagonism on dopamine release in the prefrontal area may
eventually improve emotion perception and social func-
tioning [14]. However, both FGAs and SGAs also affect
dopamine regulation in the mesocorticolimbic system,
which suggests the potential for regulation of the amy-
gdalae as an emotional manager [17].
Furthermore, clozapine and olanzapine increased
dopamine outflow in the medial prefrontal cortex (mPFC),
but not in the striatum or nucleus accumbens, whereas
haloperidol had no effect in the mPFC but increased
dopamine outflow in the striatum [47].
As a rule of thumb, frontal dopamine deficiency, per-
haps as a response to striatal overactivity, has been con-
sidered germane to the induction of negative symptoms,
associated with cognitive deficit and impaired social cog-
nition. Therefore, trials have investigated the differential
effects of FGAs and SGAs upon social cognition.
Kee et al. [32] evaluated the ability to recognise ‘‘emo-
tional’’ faces in 20 treatment-resistant patients at baseline
and after 8 weeks of treatment with risperidone or halo-
peridol, in a double-blind trial. The results of this study
confirmed the positive influence of treatment with risperi-
done on the performance of facial affect tasks. Williams
et al. [36] later reported similarly, that schizophrenic
patients on haloperidol underperformed those on risperi-
done and healthy controls in recognising facial emotional
expressions. Haloperidol-treated patients showed reduced
fixation (attention) to salient features for neutral and happy
expressions whereas risperidone-treated subjects and heal-
thy controls achieved comparable results, displaying
significantly better fixation to salient features for these
expressions. This was followed by Littrell et al. [44] who in
an open study found that 22 schizophrenia patients treated
with olanzapine for 12 months performed better on a social
perception measure, the Interpersonal Perception Task, than
30 patients on FGAs.
Fakra et al. [46] reported that 25 acute schizophrenia
patients randomised to risperidone performed a facial affect
discrimination task significantly better than those treated
with haloperidol after 4 weeks. It was concluded that ris-
peridone may specifically act on the processing of emotion-
laden information: findings could not be explained on the
grounds of facial recognition alone. However, Savina and
Beninger [45] demonstrated that ToM performance in
schizophrenia patients was related to maintenance, rather
than acute treatment effects: they suggested that olanzapine
and clozapine, but not risperidone or FGAs, may improve or
protect ToM ability in this scenario.
It is worth mentioning that none of the studies above,
apart from that of Harvey et al. [29], was both randomised
and adequately powered. The lack of standardised social
cognitive measures coupled with psychopathology rating
scales detracts from their value. Common sense dictates
that the active, distressing symptoms of acutely ill patients
and the far from optimal state of arousal that these induce
must seriously impair performance of any cognitive task
that requires optimal attention and concentration. ‘Control’
tasks, to uphold the specificity of any improvement in
social cognition, are conspicuous by their absence.
Consistent with the conclusion that these positive find-
ings may be more apparent than real is a substantial body
of literature reflecting far fewer differences between atyp-
ical and conventional antipsychotic drugs than initially
suggested [48].
Of enormous influence is the CATIE trial (Clinical
Antipsychotic Trials for Intervention Effectiveness trial),
which failed to demonstrate differential antipsychotic
effects on social cognition. To wit, Penn et al. [33] assessed
emotion perception in 873 CATIE patients randomised to
quetiapine, olanzapine, risperidone, ziprasidone (all SGAs),
or perphenazine (FGA). Patients completed the Face
Emotion Discrimination Task [49] immediately prior to
randomisation and after 2 months of treatment. At baseline,
60 % of participants were on a SGA, 15 % on a FGA, and
25 % of subjects were antipsychotic free. Non-statistically
significant improvement in emotion perception at 2 months
was observed: the treatment groups did not differ from one
another.
Finally, Kucharska-Pietura et al. [35] assessed deficits in
social cognitive functioning in a naturalistic pragmatic
sample of partially remitted stable schizophrenia inpa-
tients, 28 being treated with a FGA (perphenazine or hal-
operidol), 56 being treated with a SGA (olanzapine or
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clozapine), and 50 healthy controls. In line with previous
findings, there were no differences between the patient
groups in emotional perception and ToM/empathy. This is
particularly striking given the supposedly superior effects
of clozapine previously reported. There were small but
significant advantages for SGAs in non-social low-level
visual processing: this was thought to result from SGAs’
weaker antagonism of dopamine receptors in the retina
[35].
4 Conclusions
First, overall, antipsychotic drugs of either class demon-
strate little reliable effect upon social cognition [38, 50].
There is a modicum of support for the use of oxytocin as an
adjunct to antipsychotic drugs [11] but whether this latest
finding is a valid effect remains a matter of conjecture. By
contrast, recent randomized intervention studies of spec-
ialised psychosocial treatment programmes for social
cognition report very promising results in the improvement
of emotional perception and social skills in schizophrenia
[50–52].
Secondly, the literature suffers from inconsistencies in
study design, particularly a prevalence of non-randomised
approaches based upon cross-sectional assessments, which
do not reflect the later NIMH recommendations. Nor are
medication doses standardised. Most sample sizes are quite
small, and there is inadequate control of pertinent clinical
variables. This overlaps with three obstacles to research
progress identified by the NIMH group: (1) psychometrics
and measurement, (2) maturity of the field, and (3) a lack of
interdisciplinary bridges between clinical and basic
researchers [39].
Finally, large-scale longitudinal investigations are nee-
ded to explore the unclear relationships between social
cognition, symptoms, and functional outcome. If social
cognition proves to represent a neurocognitive construct,
we suspect related to premorbid personality, then it is not
logical to expect current antipsychotic treatments designed
to attenuate active symptoms to have any significant effect
other than through symptom control, thus abolishing the
‘noise’ of symptoms in the patient’s attempts at social
cognitive function. Other treatments, quite possibly train-
ing patients in the areas in which they are impaired, may
hold more promise.
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